Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because of decreased
insulin activity and/or insulin secretion. Pathological changes such as nephropathy …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic
drugs that have shown improvement in renal and cardiovascular outcomes in patients with …

The incidence and prevalence of metabolic and musculoskeletal diseases are increasing.
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, inflammation …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

SGLT2 inhibitors are medications that have a unique mechanism of action and that lower
glucose independent of insulin. Given the recent findings on efficacy and benefits, these …

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …